Latest & greatest articles for alendronate

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on alendronate or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on alendronate and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for alendronate

21. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy

Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy 18802155 2008 09 19 2008 10 09 2016 12 15 1527-7755 26 27 2008 Sep 20 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. 4426-34 10.1200/JCO.2007.15.1233 (...) Androgen-deprivation therapy (ADT) for prostate cancer is associated with bone loss and osteoporotic fractures. Our objective was to examine changes in bone density and turnover with sustained, discontinued, or delayed oral bisphosphonate therapy in men receiving ADT. A total of 112 men with nonmetastatic prostate cancer receiving ADT were randomly assigned to alendronate 70 mg once weekly or placebo in a double-blind, partial-crossover trial with a second random assignment at year 2 for those who initially

EvidenceUpdates2008 Full Text: Link to full Text with Trip Pro

22. Continuing alendronate for an additional 5 years maintained bone mineral density in postmenopausal women

Continuing alendronate for an additional 5 years maintained bone mineral density in postmenopausal women Continuing alendronate for an additional 5 years maintained bone mineral density in postmenopausal women | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Continuing alendronate for an additional 5 years maintained bone mineral density in postmenopausal women Article Text Therapeutics Continuing alendronate for an additional 5 years maintained bone mineral density in postmenopausal women Statistics from Altmetric.com No Altmetric data available

Evidence-Based Medicine (Requires free registration)2008

23. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International

A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International 18324951 2008 03 07 2008 07 31 2015 11 19 1742-1241 62 4 2008 Apr International journal of clinical practice Int. J. Clin. Pract. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International. 575-84 10.1111/j.1742 (...) -1241.2008.01704.x To compare alendronate 70 mg once weekly (OW) with risedronate 35 mg OW with respect to change in bone mineral density (BMD), biochemical markers and upper gastrointestinal (UGI) tolerability over 24 months. This was a 12-month extension to the Fosamax Actonel Comparison Trial international study (FACTS). Postmenopausal women with osteoporosis randomly assigned to either alendronate 70 mg OW or risedronate 35 mg OW for the 12-month base study continued taking the same double-blind study

EvidenceUpdates2008

24. Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands

Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom (...) that the alendronate vitamin D3 combination was cost-effective in women aged 70 years or older with osteoporosis, and in women aged 60 years or older with a history of vertebral fracture. The methodology was appropriate and the methods used and the results were appropriately reported. The authors' conclusions appear to be appropriate given the scope of the study. Type of economic evaluation Cost-utility analysis Study objective The objective was to evaluate the cost-effectiveness of a fixed dose combination

NHS Economic Evaluation Database.2008

25. Alendronate prevents osteoporotic fractures in at risk postmenopausal women

Alendronate prevents osteoporotic fractures in at risk postmenopausal women PEARLS Practical Evidence About Real Life Situations PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners. They are funded by the New Zealand Guidelines Group. PEARLS provide guidance on whether a treatment is effective or ineffective. PEARLS are prepared as an educational resource and do not replace clinician judgement in the management of individual cases. View PEARLS online (...) at: www.cochraneprimarycare.org Alendronate prevents osteoporotic fractures in at risk postmenopausal women Clinical question How effective is alendronate in the primary and secondary prevention of osteoporotic fractures in postmenopausal women? Bottom line At an alendronate dose of 10 mg per day, both clinically important and statistically significant reductions in vertebral (NNT*16), non-vertebral (NNT 50), hip (NNT 100) and wrist (NNT 50) fractures were observed for secondary prevention but there were no significant

Cochrane PEARLS2008

26. Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis

Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis Grima D T, Papaioannou A, Thompson M F (...) , Pasquale M K, Adachi J D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of risedronate in comparison with generic or brand alendronate, for the treatment of osteoporotic women, aged 65 years

NHS Economic Evaluation Database.2008

27. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the&#160

Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the  Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women | Guidance and guidelines | NICE Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women Technology (...) appraisal guidance [TA161] Published date: 27 October 2008 Last updated: 01 January 2011 Share Guidance on alendronate (Fosamax), etidronate (Didronel), risedronate (Actonel), raloxifene (Evista), strontium ranelate (Protelos) and teriparatide (Forsteo) for preventing osteoporotic fragility fractures in postmenopausal women who have osteoporosis. This guidance replaces NICE technology appraisal guidance on the clinical effectiveness and cost effectiveness of technologies for the secondary prevention

National Institute for Health and Clinical Excellence - Technology Appraisals2008

28. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (amended) (TA160)

Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (amended) (TA160) Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women | Guidance and guidelines | NICE Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility (...) fractures in postmenopausal women Technology appraisal guidance [TA160] Published date: 27 October 2008 Last updated: 01 January 2011 Share Guidance on alendronate (Fosamax), etidronate (Didronel), risedronate (Actonel), raloxifene (Evista) and strontium ranelate (Protelos) for the primary prevention of osteoporotic fragility fractures in postmenopausal women. Guidance development process Is this guidance up to date? and we are updating this guidance. See the for progress on the update. Your

National Institute for Health and Clinical Excellence - Technology Appraisals2008

29. Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland

Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland Schwenkglenks M, Lippuner K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared population-based dual-energy X-ray absorptiometry (DXA) screening followed by treatment with alendronate (FOSAMAX; Merck & Co) versus no screening or drug treatment for osteopenia and osteoporosis. The main screening ages were 65, 75 and 85 years. The three treatment options compared were treatment with alendronate for 5 years with full

NHS Economic Evaluation Database.2007

30. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.

Teriparatide or alendronate in glucocorticoid-induced osteoporosis. 18003959 2007 11 16 2007 11 21 2015 11 19 1533-4406 357 20 2007 Nov 15 The New England journal of medicine N. Engl. J. Med. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. 2028-39 Bisphosphonate therapy is the current standard of care for the prevention and treatment of glucocorticoid-induced osteoporosis. Studies of anabolic therapy in patients who are receiving long-term glucocorticoids and are at high (...) risk for fracture are lacking. In an 18-month randomized, double-blind, controlled trial, we compared teriparatide with alendronate in 428 women and men with osteoporosis (ages, 22 to 89 years) who had received glucocorticoids for at least 3 months (prednisone equivalent, 5 mg daily or more). A total of 214 patients received 20 microg of teriparatide once daily, and 214 received 10 mg of alendronate once daily. The primary outcome was the change in bone mineral density at the lumbar spine

NEJM2007

31. Adrovance (alendronate sodium trihydrate / colecalciferol)

Adrovance (alendronate sodium trihydrate / colecalciferol) EMEA 2007 1/2 SCIENTIFIC DISCUSSION 1. Introduction This application has been submitted as an informed consent application in accordance with Article 10c of Directive 2001/83/EC, as amended. Therefore, consent from the MAH of the FOSAVANCE application, which had been submitted as a full application under Art 8(3) of Directive 2001/83/EC as amended, has been given allowing access to Module 2 to Module 5 of the initial dossier (...) in the product information. However, the applicant is asked to provide an updated Risk Management Plan taken into account the comments raised during the assessment, at the time of the first PSUR. 6. Overall conclusions, risk/benefit assessment and recommendation Since this application is an informed consent of the FOSAVANCE application, the CHMP considered that the risk-benefit balance of ADROVANCE (70 mg alendronic acid as alendronate sodium trihydrate and /70 micrograms colecalciferol) tablet given once

European Medicines Agency - EPARs2007

33. Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy raloxifene, or alendronate

Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy raloxifene, or alendronate Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy raloxifene, or alendronate Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy raloxifene, or alendronate Mobley L R, Hoerger T J, Wittenborn J S, Galuska D A, Rao J K Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined a strategy of screening women for osteoporosis at age 65 years, and treatment for those who tested positive. The three alternative treatments considered were hormone replacement therapy (HRT), raloxifene and alendronate. All women were screened using

NHS Economic Evaluation Database.2006

34. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis

The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis Liu H, Michaud K, Nayak S, Karpf D B, Owens D K, Garber A M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined three treatment strategies for postmenopausal women with severe osteoporosis: usual care (UC) based on calcium or vitamin D plus 5 years of alendronate therapy (alendronate alone); UC plus 2 years of teriparatide therapy (teriparatide alone); and UC plus 2 years of teriparatide therapy followed

NHS Economic Evaluation Database.2006

35. Cost-effectiveness of vertebral fracture assessment to detect prevalent vertebral deformity and select postmenopausal women with a femoral neck T-score > -2.5 for alendronate therapy: a modeling study

Cost-effectiveness of vertebral fracture assessment to detect prevalent vertebral deformity and select postmenopausal women with a femoral neck T-score > -2.5 for alendronate therapy: a modeling study Cost-effectiveness of vertebral fracture assessment to detect prevalent vertebral deformity and select postmenopausal women with a femoral neck T-score > -2.5 for alendronate therapy: a modeling study Cost-effectiveness of vertebral fracture assessment to detect prevalent vertebral deformity (...) and select postmenopausal women with a femoral neck T-score > -2.5 for alendronate therapy: a modeling study Schousboe J T, Ensrud K E, Nyman J A, Kane R L, Melton L J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of vertebral

NHS Economic Evaluation Database.2006

36. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis.

Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. 16914703 2006 08 17 2006 08 21 2014 06 20 1533-4406 355 7 2006 Aug 17 The New England journal of medicine N. Engl. J. Med. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. 675-84 Treatment with glucocorticoids is associated with bone loss starting soon after therapy is initiated and an increased risk of fracture. We performed a randomized, double-placebo, double-blind clinical trial of 18 months' duration (...) among patients with a rheumatic disease who were starting glucocorticoids at a daily dose that was equivalent to at least 7.5 mg of prednisone. A total of 201 patients were assigned to receive either alendronate (10 mg) and a placebo capsule of alfacalcidol daily or alfacalcidol (1 microg) and a placebo tablet of alendronate daily. The primary outcome was the change in bone mineral density of the lumbar spine in 18 months; the secondary outcome was the incidence of morphometric vertebral deformities

NEJM2006

37. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. 17190893 2006 12 27 2007 01 04 2016 10 17 1538-3598 296 24 2006 Dec 27 JAMA JAMA Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. 2927-38 The optimal duration of treatment of women with postmenopausal osteoporosis is uncertain. To compare (...) the effects of discontinuing alendronate treatment after 5 years vs continuing for 10 years. Randomized, double-blind trial conducted at 10 US clinical centers that participated in the Fracture Intervention Trial (FIT). One thousand ninety-nine postmenopausal women who had been randomized to alendronate in FIT, with a mean of 5 years of prior alendronate treatment. Randomization to alendronate, 5 mg/d (n = 329) or 10 mg/d (n = 333), or placebo (n = 437) for 5 years (1998-2003). The primary outcome measure

JAMA2006

38. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis

A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again

NIHR HTA programme2005

39. Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women.

Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. BACKGROUND: Treatment guidelines recommend drug treatment to prevent fractures for some postmenopausal women who have low bone mass (osteopenia) but do not have osteoporosis or a history of clinical fractures. OBJECTIVE: To estimate the societal costs and health benefits of alendronate drug treatment to prevent fractures in postmenopausal women with osteopenia. DESIGN: Markov model with 8 health states: no fracture (...) , post-distal forearm fracture, post-clinical vertebral fracture, post-radiographic (but clinically inapparent) vertebral fracture, post-hip fracture, post-hip and vertebral fractures, post-other fracture, and death. DATA SOURCES: Population-based studies of age-specific fracture rates and costs, prospectively measured estimates of disutility after fractures, and the Fracture Intervention Trial of alendronate versus placebo to prevent fracture. TARGET POPULATION: Postmenopausal women 55 to 75 years

Annals of Internal Medicine2005

40. Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women

Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women Papapoulos S E, Quandt S A, Liberman U A, Hochberg M C, Thompson D E CRD summary This review assessed alendronate for preventing hip fractures in postmenopausal women. The authors (...) concluded that alendronate was associated with reductions in hip fracture rates in women with postmenopausal osteoporosis. The evidence presented in the review appears to support the authors' conclusions, but poor reporting of the review methods means that the reliability of the conclusions is unclear. Authors' objectives To evaluate the effects of alendronate for preventing hip fractures in postmenopausal women, and to examine the consistency of effects among different populations. Searching MEDLINE

DARE.2005